BIOLASE Past Earnings Performance
Past criteria checks 0/6
BIOLASE's earnings have been declining at an average annual rate of -7.3%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 11.4% per year.
Key information
-7.3%
Earnings growth rate
71.6%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 11.4% |
Return on equity | n/a |
Net Margin | -34.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Biolase partners with dental speciality programs across U.S.
Aug 31BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity
Jul 21BIOLASE amends senior secured term loan with SWK Funding
Jul 01BIOLASE: Bad News Across The Board - Sell
Mar 21Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?
Feb 24BIOLASE - Speculative Buy After Strong Preliminary Q4 Results
Jan 11BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors
Nov 24Revenue & Expenses Breakdown
How BIOLASE makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 46 | -16 | 24 | 5 |
30 Jun 24 | 46 | -27 | 26 | 5 |
31 Mar 24 | 49 | -38 | 27 | 6 |
31 Dec 23 | 49 | -38 | 28 | 6 |
30 Sep 23 | 50 | -42 | 32 | 6 |
30 Jun 23 | 51 | -38 | 34 | 7 |
31 Mar 23 | 49 | -30 | 34 | 7 |
31 Dec 22 | 48 | -29 | 34 | 7 |
30 Sep 22 | 47 | -24 | 33 | 7 |
30 Jun 22 | 44 | -19 | 30 | 6 |
31 Mar 22 | 41 | -14 | 28 | 6 |
31 Dec 21 | 39 | -17 | 27 | 6 |
30 Sep 21 | 35 | -18 | 25 | 6 |
30 Jun 21 | 32 | -32 | 24 | 5 |
31 Mar 21 | 26 | -36 | 22 | 5 |
31 Dec 20 | 23 | -34 | 21 | 4 |
30 Sep 20 | 24 | -32 | 21 | 4 |
30 Jun 20 | 27 | -20 | 23 | 4 |
31 Mar 20 | 32 | -19 | 25 | 4 |
31 Dec 19 | 38 | -18 | 25 | 5 |
30 Sep 19 | 41 | -21 | 27 | 5 |
30 Jun 19 | 43 | -20 | 27 | 5 |
31 Mar 19 | 46 | -21 | 29 | 5 |
31 Dec 18 | 46 | -22 | 30 | 5 |
30 Sep 18 | 46 | -18 | 28 | 5 |
30 Jun 18 | 46 | -18 | 27 | 6 |
31 Mar 18 | 46 | -22 | 27 | 6 |
31 Dec 17 | 47 | -21 | 26 | 6 |
30 Sep 17 | 48 | -21 | 27 | 7 |
30 Jun 17 | 50 | -22 | 28 | 7 |
31 Mar 17 | 52 | -17 | 28 | 7 |
31 Dec 16 | 52 | -18 | 27 | 8 |
30 Sep 16 | 52 | -16 | 26 | 7 |
30 Jun 16 | 50 | -16 | 26 | 7 |
31 Mar 16 | 48 | -19 | 28 | 7 |
31 Dec 15 | 48 | -20 | 29 | 7 |
30 Sep 15 | 47 | -22 | 26 | 7 |
30 Jun 15 | 48 | -20 | 27 | 6 |
31 Mar 15 | 47 | -19 | 27 | 5 |
31 Dec 14 | 47 | -19 | 31 | 5 |
30 Sep 14 | 49 | -17 | 31 | 4 |
30 Jun 14 | 49 | -18 | 30 | 4 |
31 Mar 14 | 53 | -14 | 28 | 4 |
31 Dec 13 | 56 | -11 | 28 | 4 |
Quality Earnings: BIOL.Q is currently unprofitable.
Growing Profit Margin: BIOL.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOL.Q is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.
Accelerating Growth: Unable to compare BIOL.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOL.Q is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.4%).
Return on Equity
High ROE: BIOL.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.